GlaxoSmithKline Exits BIO, Pharmaceutical Giants Are Pulling Out!
In the recent period of time, according to the report of FIERCE Pharma, following Takeda, Pfizer, UCB, Wuxi Apptec and other well-known pharmaceutical companies have announced their withdrawal, another multinational pharmaceutical giant - GlaxoSmithKline (GSK) has also announced its decision to withdraw from the Biotechnology Innovation Organization (BIO) in 2025.
In an emailed statement, a spokesperson for British drugmaker GSK said that following an annual review of its corporate membership and trade association participation, the company decided not to renew its BIO membership for 2025. The company representative further added, "We remain committed to fostering a policy environment that prioritizes disease prevention, addresses barriers to health equity and access, and incentivizes sustainable innovation." At the moment, we think there are other areas where we can focus our resources."
Since December last year, several large pharmaceutical companies have announced their withdrawal from BIO. Pfizer and Urbyx exited BIO in December 2023 and January 2023, respectively, while AbbVie cut ties with BIO in 2022. On March 13, 2024, Wuxi Apptec withdrew due to BIO's support for the BioSafety Act, which was confirmed by the U.S. House of Representatives, specifically targeting five Chinese life science companies, including Wuxi Apptec and Wuxi Bio.
With the signing of the Inflation Reduction Act (IRA) by the Biden administration in August 2022, drug prices are facing unprecedented challenges. BIO and PhRMA appealed one after another, but in the case of high investment, they still failed to stop the government's intervention in drug prices. This has also directly led to the withdrawal of major pharmaceutical companies.
2026-10-13
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
DKSH Expands Partnership with Assessa to Distribute Botanical Ingredients Across China
-
EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows
-
EU May Build Industry-Level Trade Barriers Against Chinese Chemicals
-
China’s TiO₂ Industry Launches Sixth Price Hike Wave as More Than 20 Producers Follow
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
APVMA Suspends Dimethoate Use on Select Berries Amid Updated Exposure Assessment
Recommend Reading
-
Celanese to Close Acetate Tow Plant in Lanaken, Belgium by 2026
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
-
Major Fire Hits China-Russia Joint 2.7 Million T/Y Polyolefins Project, Killing 6 Chinese Nationals and Injuring 152 People
-
Wanhua's BorsodChem Restarts 650,000 T/Y of MDI and TDI Capacity in Europe
-
South Korea Tests Arctic Commercial Route as Asian Exporters Seek New Logistics Alternatives
-
Ammonium Sulfate Market Trend Weakens and Declines (10.23-10.29)
-
Business Society’s Market Outlook for Fuel Oil 180CST on August 25, 2026: Volatile
-
October DMF Market Prices Weakly Decline
-
Business Society’s Market Outlook for Natural Rubber on August 25, 2026: Strong Consolidation with a Slight Bullish Bias
-
Supply and Demand Pressures Combine, PVC Prices Surge and Then Retreat This Week